MALDI-TOF mass spectrometry has revolutionized pathogen identification by shortening this step by 24h compared to traditional biochemical tests. In contrast, the antibiotic therapy choice remains largely driven by conventional antibiotic susceptibility testing, hence with a delay of 18-24h after ID. Commercially available products exist today for quicker determination of resistance determinants, either based on imaging, molecular biology tools, or on colorimetric and immuno-chromatographic testing. There is however no universal technology available for rapid (t<6hrs), cost effective, concomitant ID, AST characterization and virulence evaluation. By leveraging on an innovative in-real-time adaptive targeted mass spectrometry technology, we propose to overcome this limitation, directly from a positive blood culture, and with a time-to-result of less than an hour.